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Background
Over the last 15 years, our knowledge of stem cell biology has exponentially increased. 
The result of that there is an ever-increasing array of stem cells such as adult stem cell 
(ASC), embryonic stem cell (ESC), and induced pluripotent stem cell (iPSC). In the early 
stage of stem cell researches, ASC and ESC were extensively investigated but iPSC has 
become one of the major stem cell research fields since the development of iPSC by the 
Shinya Yamanaka group in 2007 (Litterman and Ekins 2015). In 2012, even its infancy, 
the key scientists of iPSC shared the award of Nobel Prize in Physiology and Medicine, 
emphasizing the significant of the advent of reprogramming and cell fate conversion. 
Further, scientists have become actively involved in stem cell biology and translation, 
participating in new fundamental discoveries and leading efforts into applications in 
biotechnology and medicine. Thus, the technical assessment of stem cells including this 
study might be timely and warranted.
Abstract 
Background: In general, technological levels have been assessed based on special-
ist’s opinion through the methods such as Delphi. But in such cases, results could be 
significantly biased per study design and individual expert.
Findings: In this study, therefore scientific literatures and patents were selected by 
means of analytic indexes for statistic approach and technical assessment of stem 
cell fields. The analytic indexes, numbers and impact indexes of scientific literatures 
and patents, were weighted based on principal component analysis, and then, were 
summated into the single value. Technological obsolescence was calculated through 
the cited half-life of patents issued by the United States Patents and Trademark Office 
and was reflected in technological level assessment. As results, ranks of each nation’s 
in reference to the technology level were rated by the proposed method. Furthermore 
we were able to evaluate strengthens and weaknesses thereof.
Conclusions: Although our empirical research presents faithful results, in the further 
study, there is a need to compare the existing methods and the suggested method.
Keywords: Technology level assessment, Principal component analysis, Analysis of 
scientific literatures and patents, Stem cell
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Various studies are underway on establishing methodologies for strategic research and 
development (R&D) planning, and there has been an increase in application of techno-
logical level assessment. The technological level assessment is intended to compare sci-
entific or industrial technologies of countries, industries and/or companies (Han et al. 
2010). And, a technological level, an object of assessment, can be defined as performance 
of a specific technology measured at a specific time point. In this, the assessment needs 
a comparison between either two technologies or two different time points in reference 
to technological capability.
In the present study, we assessed the technology level of stem cell research based on 
published scientific literatures and patent analysis at national levels. Specifically, we ana-
lyzed ASC, ESC, and iPSC for eleven nations: Canada (CA), China (CN), France (FR), 
Germany (DE), Israel (IL), Japan (JP), Singapore (SG), South Korea (KR), Taiwan (TW), 
United Kingdom (UK), and United States (US).
Data collection
Scientific literatures and patents for assessment of technological levels
Technological levels have been often assessed through specialized agencies. For exam-
ple, in the US, the Office of Science and Technology Policy (OSTP) has been taking a 
primary role in assessment of nation’s technological levels. In JP, they conduct the 
technological level assessment prior to laying a science and technology master plan, 
wherewith it quantitatively and qualitatively assesses the levels of core technologies. In 
addition, the Japan Science and Technology Agency–Center for Research and Develop-
ment Strategy (JST–CRDS) has been conducting international comparative assessment 
of technology level to support effective R&D policy-making since 2008. In KR, the levels 
of technologies (e.g., green technologies, information technologies, and industrial tech-
nologies) are often assessed by national agencies such as Korea Institute of Science and 
Technology Evaluation and Planning (KISTEP). The Table 1 depicts the summary of the 
recent cases of technology level assessment in different countries.
Patents are often regarded as one of the most representative technological outputs 
of R&D activities hence patents statistics might be a valuable source of information for 
technological strategy planning. It seems obvious therefore that patents statistics has 
been receiving more attention for implementing successful R&D as well as activities in 
high-tech industries such as biotechnology and information and communication tech-
nology. The Table 2 summarizes an important set of statistics used to analyze techno-
logical strategy in previous studies. The statistics were proposed for the evaluation of 
competitive positions in: number of patent, patent impact index, and cited-patent life 
time.
On the other hand, published research literatures could be also utilized as an excel-
lent indicator for technology level assessment (Garfield and Welljams-Dorof 1992). Even 
though, numbers of scientific literatures have traditionally been regarded as an indicator 
of the productivity, quality of these works should not be overlooked. Such qualitative 
analysis however, is mostly performed by experts in the field thus is an often time-con-
suming and expensive process. In order to overcome these limitations, advent of cita-
tion databases, which track how often articles are referenced in subsequent publications, 
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and by whom, have created new tools for indicating the impact of primary research lit-
eratures. By aggregating citation data, it is then possible to indicate the relative impact 
of individuals, journals, departments, institutions, and nations. In addition, the citation 
data can be used to identify emerging specialties, new technologies and even the struc-
ture of various research disciplines, fields, and science as a whole.
Obsolescence rate
A technology becomes obsolescent over time. It might have been an up-to-date tech-
nology at one time, yet it may be regarded as an obsolete technology later. Bosworth 
(1978) analyzed statistical data on knowledge lie, from the creation of new technologies 
to their obsoleteness, by using the residual materials (Bosworth 1978). The usage rate of 
new technologies rose gradually and reached the peak on the 6th year after the creation 
of new technology, and then it showed a slow decline and reached nearly zero on the 
16th year (Bosworth 1978). In the case of the manufacturing industry, for instance in 
UK, the obsolescence rate of technological knowledge estimated with renewed patents, 
reached approximately 10 %. In JP, the obsolescence rate was calculated from the recip-
rocal of average life of each industry, on the premise that the technological knowledge 
stock would decrease equally every year (KISTEP 2010). In other study, the obsolescence 
rate of R&D stock was estimated at 20 % because just 20 % of initial R&D expenses were 
developed into R&D stock (Pattel and Soete 1988). In this study, the obsolescence rate 
was estimated by the use of cited half-life (CHL). The CHL is intended to show how long 
specific journals or patents have been cited; more precisely, the period during which 
cumulative citation frequency reaches 50 %. In the study, therefore, the CHL was calcu-
lated using formula used in the Journal Citation Reports.
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Approaches for technological level assessment: current status
Technological level assessment has been conducted by different assessors for various 
technologies, yet through similar methods, whereupon it has the following limitations. 
First, technological level was assessed via qualitative methods such as Delphi or the 
focus group interview. Although the qualitative methods are easy to conduct, often these 
methods are susceptible to methodological approaches, per se (KISTEP 2011). Conse-
quently, results may be impacted per how an experimental group is composed. Second, 
the existing quantitative assessments, using scientific literatures and patent statistics, did 
not compute technological obsolescence caused by lapse of time. In practice, however, 
a technology has been obsolescent over time and become less valuable in the end, war-
ranting the novel definition to account for this. In the current study, therefore this tech-
nological obsolescence was quantitatively computed utilizing the CHL (i.e., the period 
during which cumulative citation frequency reaches 50 %), and then, reflected for the 
assessment. Further, to compensate erstwhile defects, this study focused on technolog-
ical scientific literatures and patents to which bibliometrics can be applied. The com-
posite index of technological levels was calculated with literatures and patent indexes, 
weighted through principal component analysis (PCA) whilst technological obsoles-
cence was assessed through the term, CHL.
Data collection
In the present study, the Focust database was utilized for patents, respectively. For the 
database for scientific literature, we retrieved the articles using the database, Scopus, was 
utilized since it lists the largest numbers of journals (i.e., 21,568 journals) compared to 
other databases (e.g., Science Citation Index: 3746 journals; Arts and Humanities Cita-
tion Index: 1774 journals). Specific searching conditions were described in the Table 3. 
In addition, Table 4 shows specific indicators utilized for the analysis. Quantitative indi-
cators were measured with the numbers of patents issued by the United States Patents 
and Trademark Office (USPTO) and scientific literatures listed in the database (i.e., Sco-
pus). Moreover, qualitative indicators were measured using ‘Patent Impact Index’ and 
‘Paper Impact Index.’ Such indicators were calculated in relation to every country and 
year. Every indicator was divided by the maximum value of every year, and the indicator 
values were re-scaled between 0 and 1 (Fig. 1).  
Table 2 Patent statistics for technology assessment in previous studies
Previous studies Patent statistics
Number of patents Patent impact index Cited-patent life time
Huang et al. (2003) 0 0
Ernst (2003) 0
CHI Research Inc. (2005) 0 0
Chia (2004) 0 0
Yoo et al. (2006) 0
Cho et al. (2013) 0 0
Cho and Park (2015) 0
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Statistical analysis
The PCA was utilized to reduce correlated multivariate data to low-dimensional data in 
order to prevent the loss of information, meaning simplifying complex data sets for bet-
ter interpretation (Raychaudhuri et al. 2000). PCs were generated via the summation of 
weighted variables. In this process, the weighting was determined via the optimization 
of information contained in initial variables to the end which may represent the widest 
dispersion. In case the initial variable contains a large number of principal components, 
every component should not be correlated, in other words, the inter-variable covariance 
should be 0. The relational expression was expressed in the Eq. 1 as follow:
In the formula, PC1 to PCm represent principal components while x1 to xn indicate 
initial variables; a11 to amn mean weightings. The PCs were selected when its eigenvalue 
is 1 or higher (according to the Kaiser’s rule). Weightings, regarding respective variables, 
could be calculated by the reverse use of the factor matrix between PCs and variables. In 
this study, the composite technological level was analyzed through the weightings fig-
ured out with respect to each variable.
Lastly, in order to assess the technical level of stem cell technology, four weightings 
obtained from PCA were summated into a single value, from which technological level 
index was calculated. Then, CHL was applied to the technological obsolescence rate. 
With the technological level index, technological levels were analyzed in relation to 
years and countries. The formula to assess the technology level is described as below:
(1)
PC1 = a11x1 + a12x2 + · · · + a1nxn
PC2 = a21x1 + a22x2 + · · · + a2nxn
. . .
PCm = am1x1 + am2x2 + · · · + amnxn
Table 3 Variables used for scientific literature and patent searching




 Document type Primary research articles
 Subject areas Life sciences and health sciences
Patent
 Database Focust
 Patent type Patents issued by the United States Patents and Trademark Office
Search formula
 Adult stem cell “Adult stem cell*” or [(hematopoietic or neural or mesenchymal or intestinal 
or pancreatic or retinal or Epidermal or “umbilical cord blood” or mammary 
or endothelial or olfactory or “dental pulp derive”) and “stem cell*”]
 Embryonic stem cell “Embryonic stem cell*”
 Induced pluripotent stem cell “Induced pluripotent stem cell*” or (iPS and “stem cell*”)
Miscellaneous conditions
 Date range Jan-01-1993–Dec-31-2012 (20 years)
 Country Canada, China, France, Germany, Israel, Japan, Singapore, Korea, Taiwan, 
United Kingdom, United States





((NTt × NTω)+ (PTt × PTω)× (NRt × NRω)× (PRt × PRω))× δt





the number of patent
)
, NTω = weight of NT
PT = PII_Patent (patent impact index), PTω = weight of PT
NR = NP_Paper
(
the number of paper
)
, NRω = weight of NR
PR = PII_Paper (paper impact index), PRω = weight of PR
δ = Obsolescence rate
Table 4 Indicators for scientific literatures and patent analysis
Indicators Description Calculation
Number of patents Quantity of patents The number of patents issued by the United States Patents and 
Trademark Office






Ca = the number of forward citations of patent in 
nation a
Na = the number of patent in nation a
Ct = the number of total forward citations of patents
Nt = the number of total patents
Number of papers Quantity of scientific 
literatures
The number of scientific literatures published by the Scopus






Ca = the number of forward citations of scientific 
literature in nation a
Na = the number of scientific literatures in nation a
Ct = the number of total forward citations of scien-
tific literatures
Nt = the number of total scientific literatures
Fig. 1 Assessment of technological level using quantifiable outputs, scientific literature and patent: a 
research model
Page 7 of 17Do Cho et al. SpringerPlus  (2016) 5:857 
Results and discussion
Analysis of scientific literatures and patents
Stem cell-related scientific literatures and patents (e.g., ASC, ESC, and iPS cells) were 
retrieved, and then, the NP and PII were analyzed in relation to years and countries 
(Table 5). The indexes of different units were divided by the maximum value of each year, 
and all of them re-scaled between 0 and 1 (Table 6).
PCA
In order to determine the weightings of indexes, PCA was conducted with respect to 
the indexes of published literatures and patents registered between 1993 and 2012. A 
total of 470 sets of data were used, exclusive of data of which values were 0 for four 
variables (Table 7). Then, calculations were made of four components, their eigenvalues 
and cumulative contribution rates. The eigenvalues of the PC1 and the PC2 were 2.145 
and 1.028, respectively, and their contribution rates were 53.6 and 25.7 % respectively. 
These two PCs comprised of 79.3 % of the total data set (Table 8). Eigenvalues of the two 
PCs (Table 8) and component matrix (Table 9) were used to calculate the weightings of 
indexes (Table 10).
Obsolescence rate
The CHL was calculated using the citation frequency of USPTO issued patents in order 
to determine the technological obsolescence rate. In order to analyze the citation fre-
quency, numbers of citations per each year were analyzed based on the year of registra-
tion of patents and expressed as percentile as shown in the Table 11. It indicates that 
the patent was citied 19.4 times on its 4th year from the point where it was registered 
if it was cited 100 times on the year of registration. In this, a calculation was made of 
the annual citation frequency of patents registered between 1993 and 2002. The Fig. 2 
depicts the cumulative citation frequency of every year. In the result, CHL was 9.286 
(Table 12; Fig. 2). Specifically, the patents averagely reached CHL 9.286 years after the 
registration. The Table 13 and Fig. 3 show the annual obsolescence rate on the premise 
that a technology obsolesces 50 % every 9.286 years.
Assessment of technological level
The technological level, assessed at a specific point of time, means the technological 
stock calculated up to then, and thus the cumulative value was calculated for the assess-
ment of annual technological levels. Prior to the calculation of the cumulative value, a 
time-series analysis was conducted with respect to the technological level, by the use 
of the annual obsolescence rate. The obsolescence rates shown in the Table  13 were 
reflected in the re-scaled indicators of scientific literatures and patents, and the levels of 
technologies presented every year were assessed at the present point in time (Fig. 4). As 
results, the US has the highest technological level, followed by JP, IL, CA, UK, DE, FR, 
SG, CN, KR and TW, respectively; the technological levels of Asian countries, except 
for JP, were relatively lower compared to those of European countries. In case of the US 
ranked first, 4 scientific literature and patent indicators showed high percentages with-
out significant differences. In CN, however scientific literatures accounted for a high 
percentage of the technological level, whereas patents or patent impact indexes made up 
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a very small part. IL and CA had high levels of NP but low levels of PII; overall, however 
their technological levels were relatively high.
When it comes to the ASC, the US has the highest technological level, followed by CA, 
IL, JP and DE (Table 14; Fig. 5). In case of CA, the technological level has been rapidly 
improved, in comparison with other countries, since the late 1990s. Likewise, the US 
Table 5 Results of scientific literatures and patent analysis
CA Canada, CN China, FR France, DE Germany, IL Israel, JP Japan, SG Singapore, KR Korea, TW Taiwan, UK United Kingdom, US 
United States, NP_Patent number of patents, PII_Patent Patent Impact Index, NP_Paper Number of papers, PII_Paper Paper 
Impact Index
Indicators Year CA CN DE FR UK IL JP KR SG TW US
Adult stem cell
 NP_Patent 1993 1 n/a n/a n/a n/a n/a n/a n/a n/a n/a 3⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 3 n/a 3 4 3 6 8 4 6 4 79
 PII_Patent 1993 0.42 n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.19⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.36 n/a n/a 2.96 n/a 0.18 2.22 n/a 0.81 n/a 1.06
 NP_Paper 1993 1 n/a 5 4 4 1 6 n/a n/a n/a 37⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 80 747 169 105 137 33 194 198 30 64 694
 PII_Paper 1993 0.58 n/a 1.01 0.74 2.77 0.60 0.50 n/a n/a n/a 0.94⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 1.04 0.49 1.32 1.12 1.56 0.95 0.88 0.87 1.32 0.77 1.42
Embryonic stem cell
 NP_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 1 n/a n/a 1 3 2 10 2 3 1 55
 PII_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 1.99 n/a 0.28 n/a 1.04
 NP_Paper 1993 2 n/a 6 1 4 1 2 n/a n/a n/a 14⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 31 109 54 25 67 18 56 44 20 10 261
 PII_Paper 1993 6.43 n/a 0.85 0.02 0.10 0.37 0.15 n/a n/a n/a 0.78⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.95 0.70 0.93 1.17 1.23 0.60 0.86 0.51 0.87 0.34 1.25
Induced pluripotent stem cell
 NP_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 4 n/a n/a 1 2
 PII_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 1.75 n/a n/a n/a n/a
 NP_Paper 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 7 51 18 9 12 6 63 7 1 11 111
 PII_Paper 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 1.64 0.66 0.81 1.76 1.86 1.29 0.69 0.84 0.62 1.07 1.16
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was rated first in the field of ESC and SG was the second, followed by IL and DE. When 
it comes to the ASC, countries did not show any significant difference, except for the US. 
In the field of ESC, SG, IL, DE, UK, JP, CA and FR constituted a group, while KR, CN 
and TW represented another group. There was remarkable difference between the two 
groups (Table 14; Fig. 5).
Table 6 Re-scaled indexes
CA Canada, CN China, FR France, DE Germany, IL Israel, JP Japan, SG Singapore, KR Korea, TW Taiwan, UK United Kingdom, US 
United States, NP_Patent number of patents, PII_Patent Patent Impact Index, NP_Paper number of papers, PII_Paper Paper 
Impact Index
a 0.33 is calculated from the result of re-scaling; 1 (NP_Patent of CA in 1993)/3 (NP_Patent of US (maximum value) in 1993)
Indicators Year CA CN DE FR UK IL JP KR SG TW US
Adult stem cell
 NP_Patent 1993 0.33a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.00⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.04 n/a 0.04 0.05 0.04 0.08 0.10 0.05 0.08 0.05 1.00
 PII_Patent 1993 0.35 n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.00⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.12 n/a n/a 1.00 n/a 0.06 0.75 n/a 0.27 n/a 0.36
 NP_Paper 1993 0.03 n/a 0.14 0.11 0.11 0.03 0.16 n/a n/a n/a 1.00⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.11 1.00 0.23 0.14 0.18 0.04 0.26 0.27 0.04 0.09 0.93
 PII_Paper 1993 0.09 n/a 0.16 0.12 0.43 0.09 0.08 n/a n/a n/a 0.15⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.56 0.26 0.71 0.60 0.84 0.51 0.47 0.47 0.71 0.41 0.76
Embryonic stem cell
 NP_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.01 n/a n/a 0.01 0.04 0.03 0.13 0.03 0.04 0.01 0.70
 PII_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 0.67 n/a 0.09 n/a 0.35
 NP_Paper 1993 0.05 n/a 0.16 0.03 0.11 0.03 0.05 n/a n/a n/a 0.38⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.04 0.15 0.07 0.03 0.09 0.02 0.07 0.06 0.03 0.01 0.35
 PII_Paper 1993 1.00 n/a 0.13 0.00 0.02 0.06 0.02 n/a n/a n/a 0.12⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.51 0.37 0.50 0.63 0.66 0.32 0.46 0.28 0.47 0.18 0.67
Induced pluripotent stem cell
 NP_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 0.05 n/a n/a 0.01 0.03
 PII_Patent 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 n/a n/a n/a n/a n/a n/a 0.59 n/a n/a n/a n/a
 NP_Paper 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.01 0.07 0.02 0.01 0.02 0.01 0.08 0.01 0.00 0.01 0.15
 PII_Paper 1993 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮ ⋮
2012 0.88 0.35 0.44 0.94 1.00 0.69 0.37 0.45 0.33 0.58 0.62
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SG was found to be inferior to North American and European countries in the field of 
ASC as well as iPSC, yet in the ESC, it was the second highest country after the US. Of 
note, the technological level of human embryonic stem cell (hESC) was particularly high, 
hence, in a way to support the feasibility of the analysis result, we further reviewed the 
current hESC banks of each country (Korea Centers for Disease Control and Prevention, 
Table 7 Simple statistics of variables and their correlation coefficients
NP_Patent number of patents, PII_Patent Patent Impact Index, NP_Paper number of papers, PII_Paper Paper Impact Index
a 20 (years) × 11 (countries) × 3 (adult stem cell, embryonic stem cell, iPS cell)—190 (the number of cases when four 
indicators (NP_Patent, PII_Patent, NP_Paper, PII_Paper) are all n/a) = 470
Na Mean Standard deviation NP_Patent PII_Patent NP_Paper PII_Paper
NP_Patent 470 0.091 0.234 1.000
PII_Patent 470 0.173 0.296 0.556 1.000
NP_Paper 470 0.149 0.232 0.741 0.333 1.000
PII_Paper 470 0.404 0.266 0.146 0.224 0.017 1.000
Table 8 Eigenvalue and cumulative variance of principal components (PCs)
PC1 and PC2 were selected as their eigenvalues are higher than 1
PCs Eigenvalue Variance (%) Cumulative variance (%)
PC1 2.15 53.62 53.62
PC2 1.03 25.70 79.33
PC3 0.62 15.42 94.75
PC4 0.21 5.25 100.00
Table 9 Component matrix






Table 10 Weights for statistics used in assessment of technological level
NP_Patent number of patents, PII_Patent Patent Impact Index, NP_Paper number of papers, PII_Paper Paper Impact Index
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2013). As expected, Singapore Stem Cell Consortium (SSCC) particularly focused on 
the hESC over other stem cell types; in fact it appeared that the SSCC developed clini-
cal grade hESC in 2007 via their good manufacturing practice facilities. The Singapore 
Stem Cell Bank which is operated by the SSCC is currently selling four clinical grade 
hESC stocks as well (Korea Centers for Disease Control and Prevention 2013). It has 
been widely accepted that the development of clinical grade hESC requires cutting-edge 
technology which results only two countries have been successful so far (i.e., US and 
SG). To be specific, the US has developed two clinical grade cell stocks, while SG devel-
oped six clinical grade cell stocks (Crook et al. 2007). Given that, it seems reasonable to 
believe that the technological level of SG in the field of hESC stands out. The US stands 
Table 11 Percentage of citation frequency after patents issued
Issue year Y + 0 Y + 1 Y + 2 Y + 3 Y + 4 Y + 5 Y + 6 Y + 7 Y + 8 Y + 9 Y + 10
1993 0.0 0.0 6.0 3.0 19.4 6.0 17.9 13.4 6.0 11.9 6.0
1994 0.0 2.9 0.0 5.7 2.9 0.0 5.7 8.6 2.9 2.9 5.7
1995 0.0 0.4 3.2 4.2 5.6 7.3 5.9 4.2 4.3 4.5 3.6
1996 0.1 0.4 2.5 3.0 3.4 4.8 5.6 5.4 4.3 4.4 5.2
1997 0.1 0.3 2.3 3.8 4.0 3.8 5.5 6.4 4.5 6.8 6.5
1998 0.0 0.8 1.9 2.5 3.1 4.7 4.3 4.3 7.1 5.7 8.5
1999 0.1 0.6 2.3 2.9 4.8 4.3 3.2 6.8 6.1 9.2 12.4
2000 0.0 0.8 2.1 4.4 4.9 6.2 6.0 6.7 8.4 12.9 15.9
2001 0.0 0.5 3.0 2.6 3.0 6.0 7.9 9.0 9.8 17.6 15.0
2002 0.0 0.8 0.5 1.0 2.5 4.8 7.3 12.3 14.5 20.0 28.7
Mean 0.0 0.8 2.4 3.3 5.3 4.8 6.9 7.7 6.8 9.6 10.7
Issue year Y + 11 Y + 12 Y + 13 Y + 14 Y + 15 Y + 16 Y + 17 Y + 18 Y + 19 Y + 20 Total
1993 0.0 1.5 1.5 0.0 0.0 0.0 4.5 1.5 1.5 0.0 100.0
1994 0.0 8.6 14.3 8.6 11.4 2.9 11.4 5.7 0.0 – 100.0
1995 6.0 4.3 6.8 8.2 10.2 8.7 10.6 2.0 – – 100.0
1996 5.1 7.8 7.9 11.5 11.6 13.9 3.3 – – – 100.0
1997 6.7 8.1 12.4 12.3 13.8 2.7 – – – – 100.0
1998 10.6 13.3 13.6 16.8 2.9 – – – – – 100.0
1999 13.0 14.0 17.0 3.5 – – – – – – 100.0
2000 12.7 15.7 3.2 – – – – – – – 100.0
2001 20.7 4.7 – – – – – – – – 100.0
2002 7.5 – – – – – – – – – 100.0
Mean 8.2 7.8 7.7 6.1 5.0 2.8 3.0 0.9 0.1 0.0 100.0
Fig. 2 Cumulative citation frequency after patent issued for the fields of stem cell research
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Table 12 Calculation of cited half-life (CHL)
Time lag (years) Citation frequency (%) Cumulative citation frequency (%)
Y + 0 0.0 0.0
Y + 1 0.8 0.8
Y + 2 2.4 3.1
Y + 3 3.3 6.5
Y + 4 5.3 11.8
Y + 5 4.8 16.6
Y + 6 6.9 23.5
Y + 7 7.7 31.3
Y + 8 6.8 38.0
Y + 9 9.6 47.6
Y + 10 10.7 58.4
Y + 11 8.2 66.6
Y + 12 7.8 74.4
Y + 13 7.7 82.1
Y + 14 6.1 88.2
Y + 15 5.0 93.1
Y + 16 2.8 96.0
Y + 17 3.0 98.9
Y + 18 0.9 99.9
Y + 19 0.1 100.0
Y + 20 0.0 100.0
CHL = 9 + (50 − 47.6)/(58.4 − 50) = 9.286
Table 13 Obsolescence rate
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unchallenged in the fields of ASC and ESC, while JP was the best country in the field 
of iPSC, over the US, which also makes sense given that (1) the Kyoto University was 
successful to generate the first iPSC in conjunction with the University of Wisconsin-
Madison in 2007 and (2) JP produced a Nobel Prize winner in physiology or medicine, 
for iPSC in 2012.
The Table 14 summarizes rankings of technological levels of each stem cell field. First, 
not surprisingly, the US whose total technological level was the highest represented the 
highest values in four detail indicators (i.e., NP_Patent, PII_Patent, NP_Paper and PII_
Paper) in the field of ASC. CA and IL whose total technological level was the second and 
third highest were relatively low in this field. Even though CN showed the second high-
est in number of scientific literatures (i.e., NP_Paper) after the US, it showed the lowest 
values in other indicators among the countries in comparison which partially explains 
Fig. 3 The obsolescence rate curve. The curve of obsolescence rate was created given the calculated CHL 
(9.286 years) which indicates that 50 % of the residual value would be decreased by every 9.286 years. The 
obsolescence rate at certain time point can be calculated via subtracting residual value out of 100 % (see 
Table 13 for the residual value)
Fig. 4 Technology level of stem cell (total)
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their low ranking in the total technological level (8th out of 11 countries in the study; 
Table 14).
In the field of ESC, again, the US showed the highest values in all indicators except for 
PII_Paper, and its total technological level was highest. The scores of SG and IL in NP 
Patent and NP_Paper were low, but their values in PII_Patent and PII_Paper were rela-
tively high which lead them to be placed in higher ranking in the field (2nd and 3rd out 
of 11 countries; Table 14). The technological level of CN in the field of ESC was the third 
highest in NP_Paper (alike in the field of ASC) after the US and JP, yet other indicators 
were (i.e., NP_Patent, PII_Patent, and PII_Paper) were the lowest amongst the countries.
On the other hand, due to the infancy of the field of the iPSC, the first patent was 
issued by the USPTO in 2011. Moreover, only three countries (US, JP, and TW) are hold-
ing the iPSC related patents issued by the USPTO. In this field, JP whose total score was 
Table 14 Technological levels of countries in stem cell field
The number in parentheses indicates a ranking among countries
NP_Patent number of patents, PII_Patent Patent Impact Index, NP_Paper number of papers, PII_Paper Paper Impact Index
Cell type Nation NP_Patent PII_Patent NP_Paper PII_Paper Total
Adult stem cell US 300.7 (1) 191.2 (1) 207.2 (1) 150.2 (1) 849.3 (1)
CA 22.4 (3) 109.2 (2) 22.1 (8) 134.6 (4) 288.2 (2)
IL 13.7 (5) 84.8 (3) 8.1 (10) 136.1 (3) 242.6 (3)
JP 23.9 (2) 58.8 (4) 61.1 (3) 86.0 (8) 229.8 (4)
DE 14.6 (4) 44.4 (6) 42.8 (4) 113.8 (6) 215.6 (5)
UK 5.7 (9) 19.8 (10) 28.7 (5) 145.0 (2) 199.3 (6)
FR 6.7 (7) 34.7 (7) 25.3 (7) 118.0 (5) 184.7 (7)
CN 0.4 (11) – (n/a) 142.3 (2) 25.5 (11) 168.2 (8)
SG 6.5 (8) 48.6 (5) 5.3 (11) 93.9 (7) 154.4 (9)
KR 8.6 (6) 26.9 (9) 27.1 (6) 84.0 (10) 146.7 (10)
TW 4.8 (10) 31.4 (8) 9.8 (9) 84.8 (9) 130.7 (11)
Embryonic stem cell US 170.2 (1) 183.1 (1) 83.5 (1) 131.7 (2) 568.6 (1)
SG 4.0 (8) 69.3 (3) 5.7 (10) 117.8 (4) 196.8 (2)
IL 5.5 (5) 44.6 (5) 6.8 (9) 139.8 (1) 196.7 (3)
DE 5.4 (6) 74.6 (2) 20.4 (5) 87.3 (7) 187.7 (4)
UK 10.4 (3) 34.7 (8) 20.5 (4) 118.5 (3) 184.1 (5)
JP 14.9 (2) 64.0 (4) 28.0 (2) 77.0 (8) 183.9 (6)
CA 9.5 (4) 39.7 (7) 9.5 (6) 112.0 (5) 170.7 (7)
FR 4.8 (7) 40.3 (6) 9.4 (7) 101.8 (6) 156.3 (8)
KR 2.6 (10) 5.5 (9) 8.6 (8) 53.4 (9) 70.0 (9)
CN 1.2 (11) 1.5 (11) 21.9 (3) 35.8 (11) 60.4 (10)
TW 2.7 (9) 3.0 (10) 2.0 (11) 37.5 (10) 45.2 (11)
Induced pluripotent stem cell JP 1.9 (1) 42.2 (1) 4.7 (2) 41.9 (6) 90.7 (1)
US 1.2 (2) – (n/a) 10.0 (1) 71.3 (1) 82.6 (2)
UK – (n/a) – (n/a) 1.0 (5) 64.0 (2) 65.0 (3)
IL – (n/a) – (n/a) 0.7 (6) 61.8 (3) 62.6 (4)
FR – (n/a) – (n/a) 0.6 (9) 47.4 (4) 48.0 (5)
CA – (n/a) – (n/a) 0.5 (10) 42.1 (5) 42.5 (6)
DE – (n/a) – (n/a) 1.6 (4) 36.5 (7) 38.1 (7)
KR – (n/a) – (n/a) 0.7 (7) 36.0 (9) 36.7 (8)
SG – (n/a) – (n/a) 0.3 (11) 36.1 (8) 36.5 (9)
CN – (n/a) – (n/a) 3.4 (3) 22.9 (10) 26.3 (10)
TW 0.4 (3) – (n/a) 0.7 (8) 21.5 (11) 22.5 (11)
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the highest obtained a high value in patent-related indicators (NP_Patent and PII_Pat-
ent). The US showed the highest value in scientific literatures-related indicators (NP_
Paper and PII_Paper), but they were ranked the second in the total technology level after 
the JP. If the new technology evaluation method presented in this study is applied, it is 
expected that not only the total technological level evaluation but also the comparison of 
individual indicators which compose the technological level will be possible.
This study assessed technological level utilizing a new quantitative method with a view 
to compensating limitations of the existing methods, i.e., qualitative assessment based 
on specialists’ opinion and quantitative one based on patent indicators. In this study, not 
only patents yet also scientific literatures were applied into the model as analytical indica-
tors, the number of papers (NP_Paper), the paper impact index (PII_Paper), the number 
of patents (NP_Patent) and the patent impact index (PII_Patent) hence provide impor-
tant insight for future R&D planning and establishment of related policy. There are two 
strengths of the assessment model we proposed herein compared to previous quantitative 
methods. First, a number of indexes for both scientific literatures and patents were sum-
mated into the single value based on the PCA. Although previous studies have attempted 
to summate a single value by analytic hierarchy process or specialists’ opinion (Cho and 
Park 2015), there was a limitation of multi-collinearity between indexes which may dou-
bly affect overall assessment of technology levels; thus, the authors attempted to exclude 
Fig. 5 Technology level of stem cell (technological classification)
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multi-collinearity by using the PCA. Second, the existing quantitative assessments may 
not be appropriate to take account of technological obsolescence, because both recently 
registered and former patents were calculated as simple numeric values without consid-
eration for technological obsolescence which made us to reflect it, caused by the lapse of 
time, in the technological level assessment. To achieve this, annual technological obsoles-
cence was computed through the CHL. Nonetheless, in future, it is warranted to make a 
direct comparison between existing qualitative assessment methods against the present 
results as well as the methodological approach in terms of validity and reliability. Further, 
application of additional quantifiable indicators may result more accurate assessment as 
well. Lastly, it is required to analyze various methodologies to further find the optimum 
quantitative assessment given objective data. To conclude, one cannot stress enough the 
fact that the assessment of technological level is one of the most important steps with 
regards to establishment of R&D plans and policies. Considering limitations of current 
assessments approaches (e.g., Delphi), our novel quantitative approach would provide a 
good alternative mean. In addition, it will be also interesting to combine both qualitative 
and quantitative assessments thereby providing unbiased results in future.
There are several limitations of the study. First, since the technology level is a type 
of intangible indicator thus one should not solely rely on assessment utilizing quantita-
tive data. In addition to scientific literature and patents, both quantitative and qualitative 
data (e.g., human resources, infrastructure, and clinical trials) should be comprehen-
sively employed for the assessment, if applicable. Second, in the present study, the rank-
ing of technology levels were made based on relative values determined through the 
equation. To take an example, in case of the ACS, the technology level of US was found 
to be 849.3 whereas South Korea was 146.7 (Table 14). These values can be used to rank 
nations yet should not be interpreted as the US technology level is 5.8 fold higher than 
South Korea because these values are relative values. In addition, even though we delib-
erately selected the largest database (i.e., Scopus) to retrieve scientific publications, 
there are other databases (e.g., Science Citation Index) and available that may list jour-
nals other than we were able to obtain from the Scopus. Last, in the present study, three 
major stem research fields were subjected to the analysis thus, it would be interesting 
and informative to further investigate subspecialized stem cells (e.g., cancer stem cells, 
foetal stem cells, and dental stem cells) and their technological field through the pro-
posed tool in future studies. Utilization of technology diffusion models (e.g., Bass model 
or Logistic model) for the prediction of stem cell research might be also interesting to 
examine in conjunction with current trends and outcomes herein (Rao and Kishore 
2010).
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